Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Y mAbs Therapeutics (YMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Y mAbs Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
15.13 +0.13    +0.87%
19/04 - Closed. Currency in USD ( Disclaimer )
After Hours
15.87
+0.74
+4.89%
18:08:56 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 458,895
  • Bid/Ask: 11.00 / 17.38
  • Day's Range: 14.71 - 15.41
Y mAbs Therapeutics 15.13 +0.13 +0.87%

Y mAbs Therapeutics Company Profile

 
Get an in-depth profile of Y mAbs Therapeutics, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

100

Equity Type

ORD

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Contact Information

Address 230 Park Avenue Suite 3350
New York, 10169
United States
Phone 646 885 8505
Fax -

Top Executives

Name Age Since Title
James Irvin Healy 57 2017 Independent Chairman of the Board
Johan Ernst Wedell-Wedellsborg 53 2015 Independent Director
Thomas Gad 53 2015 Founder, Chief Business Officer & Vice Chairman
Gérard Ber 65 2018 Independent Director
Laura Jean Hamill 58 2020 Independent Director
Michael Rossi 52 2023 CEO, President & Director
Ashutosh Tyagi 46 2017 Independent Director
David N. Gill 68 2017 Independent Director
Mary Tagliaferri 58 2024 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

YMAB Comments

Write your thoughts about Y mAbs Therapeutics
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nov 05, 2020 5:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11/5/20: YMAB closed at $48.70 today. That’s a gain of 21.75% from our buy price of $40. ;-)
Oct 05, 2020 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
YMAB. 10/5/20 at 11:10 AM. YMAB remains a good buy at or below $40. Last $40.17
Aug 10, 2020 1:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
8/10/20: YMAB is a buy under $40. Last: $39.96. Looks good going into the Fall ‘20.
Capstar Go
Capstar Go Apr 01, 2019 3:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What news came out friday 29th, Since this nice jump?
Jakob Vissing
Jakob Vissing Feb 02, 2019 6:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trong buy great news to come
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email